About: Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Latest price: $15.76 (+1.42%)
RLYB NASDAQ Rallybio Corp
Rallybio Corp share price
RLYB price activity
Last Price
$15.760
Change (24hr)
0.22 USD (1.42%)
Volume
59.38K
Volume (4w avg)
-
Open
$15.91
Day Range
$15.55 - $16.23
Previous Close
$15.54
Last Trade
02 Nov, 9:00 pm GMT+0
Delayed
02 Nov, 9:00 pm GMT+0
RLYB price performance
Delayed
02 Nov, 9:00 pm GMT+0
RLYB Market Signals